I am both a long-term myeloma survivor and myeloma cancer coach. Needless to say the article linked and excerpted below peeked my curiosity. I was interested not only for my own immune health but for my myeloma cancer coaching clients.
While just about everyone under the age of 70 who is diagnosed with multiple myeloma is told that they should have an autologous stem cell transplant, a growing number of myeloma specialists are questioning the pros/cons of transplants.
“In a recently published article, two myeloma experts discussed the role of autologous stem cell transplantation as an initial line of therapy in myeloma patients…”
I consider the article linked below to be another important reason to question autologous stem cell transplantation for newly diagnosed multiple myeloma patients.
If you have been diagnosed with Multiple Myeloma and are considering an ASCT, please read the facts below and then continue on to the UPI article below that.
The remission from my ASCT lasted 10 months. It is clear that autologous stem cell transplants have improved since ’95. I admit that some young MMers have enjoyed long remissions from ASCT’s. But every MMer will relapse eventually.
Several years of conventional therapies after my diagnosis led to two remissions, two relapses and “there is nothing more we can do for you. ” My oncologist told me that back in 9/97. I went into complete remission in early 1999.
I have remained in complete remission since ’99 by living an evidence-based, non-toxic, anti-MM lifestyle. While I live with many long-term side effects from my toxic therapies long ago, I think my immune system is working well.
I encourage MM coaching clients to live an evidence-based, non-toxic, anti-MM lifestyle through nutrition, supplementation, bone-health, lifestyle and mind-body therapies. Maybe the Multiple Myeloma Cancer Coaching program supports aging immune systems like mine.
Whether you are debating treatment options, currently undergoing treatment and experiencing painful side effects, or trying to figure out how to stay in remission, I want to share what I’ve learned from 22 years of full remission from Multiple Myeloma.
Join me in just a few minutes for a FREE webinar where we will:
Identify the side effects– both short and long term– specific to your chemotherapy or radiation regimen.
Learn about what integrative therapies are and how you can use them to optimize the efficacy of your specific chemotherapy while healing short term and long term side effects.
Go over the 12 pillars of the Multiple Myeloma Cancer Coaching Program and how they can help you heal.
As a part of the webinar, you will receive two of the 12 cancer coaching guides for FREE as well.
I hope you’ll join me. This information is the culmination of 22 years of my personal journey to achieve and maintain full remission from Multiple Myeloma.
“Researchers at the University of North Carolina found blood cancer patients treated with an autologous stem cell transplant showed elevated levels of expression of messenger RNA comparable to advanced aging, and at levels higher than with other stem cell transplant therapies, according to a study published in the journal EBioMedicine…
Stem cell transplants help extend survival time for blood cancer patients, and are delivered in one of two ways: Autologous transplants, taken from stores of a patient’s own stem cells, or allogeneic transplants, which uses stem cells from a donor…
“We know that years after a curative transplant, stem cell transplant survivors are at increased risk for blood problems that can occur with aging, such as reduced immunity, increased risk for bone marrow failure, and increased risk of blood cancers. What is important about this work, however, is that it allows us to quantify the effect of stem cell transplant on molecular age…”
“We know that transplant is life-prolonging, and in many cases, it’s life-saving, for many patients with blood cancers and other disorders,” said Dr. William Wood, an associate professor in the UNC School of Medicine’s Division of Hematology and Oncology and lead author of the study. “At the same time, we’re increasingly recognizing that survivors of transplant are at risk for long-term health problems, and so there is interest in determining what markers may exist to help predict risk for long-term health problems, or even in helping choose which patients are best candidates for transplantation…””